Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
US FDA approval based on NEURO-TTRansform Phase III results showing Wainua demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life. Additional regulatory reviews underway in rest of world. AstraZeneca and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.[1] Wainua is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.[2-4] The approval by